Supernus Pharmaceuticals releases first quarter numbers Supernus Pharmaceuticals, a specialty pharmaceutical company, recently released its consolidated financial numbers from the first quarter of 2012. The company marked a significant milestone by going public in May.

The company reported cash proceeds of $47.6 million from the initial public offering of common stocks, following financing costs estimated at $3.3 million.

"We are very excited to be a public company, and look forward to building a successful commercial enterprise, starting with the launch of our first two central nervous system, or CNS, products," said Jack Khattar, president and CEO of Supernus. "We continue to have an active dialogue with the FDA regarding the filings for SPN-538 and SPN-804. We continue to build out the infrastructure for both the sales and marketing commercial teams as planned."

General and administrative expenses for the first quarter was $2.7 million, a significant increase from the $1.7 million reported in 2011.

In other news related to the worldwide pharma supply chain, Anderson Packaging and Brecon Pharmaceuticals recently combined to create a single global pharmaceutical packaging service provider, which will feature 12 facilities across two continents. The two companies will also combine to account for more than 1,500 associates who will work to manufacture products for medical treatment.
Share To:

Strategic Sourceror

Post A Comment:

0 comments so far,add yours